NewAmsterdam Entered into an Exclusive License Agreement with Menarini Group to Commercialize Obicetrapib for Cardiovascular Diseases in EU
Shots:
- NewAmsterdam to receive a total deal value of ~$1.05B incl. $120.90M up front, $28.91M in R&D funding & will be eligible to receive ~$907.33M in clinical, regulatory & commercial milestones along with royalties on net sales of obicetrapib in EU. The companies will work together to gain the product's regulatory approval
- NewAmsterdam to get all rights to commercialize obicetrapib globally if approved & obtain rights to develop the forms of obicetrapib for other diseases incl. AD. The collaboration combines NewAmsterdam's obicetrapib with Menarini's CV disease & regional expertise
- NewAmsterdam will lead the clinical development of obicetrapib. Menarini will be responsible for all commercialization activities in the licensed territory
Ref: PRNewswire | Image: NewAmsterdam Pharma
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
